Scientists at last may have determined how mental retardation develops in people with fragile X syndrome, a condition caused by the inherited loss of an essential protein, termed the fragile X mental retardation protein (FMRP). The new research demonstrates that FMRP controls the fate of several specific proteins in brain cells and thus may explain why the absence of this single protein can cause the range of physical, cognitive and behavioral abnormalities characteristic of fragile X syndrome.
While these findings may not lead to a cure for fragile X syndrome, they do offer the potential for future therapies that would lessen the impact of the disease.
"This work represents a new understanding of mental retardation," says Robert B. Darnell, M.D., Ph.D., a principal investigator of the current research and a professor at The Rockefeller University. "Our findings suggest entirely new ways of thinking about treating the problems these patients have."
Katie Clapp, president of the FRAXA Research Foundation, which largely funded Darnell's work, and mother of two children with fragile X says, "For the first time, scientists can explain why these children experience certain symptoms. This kind of knowledge is very reassuring to the families of children with the disorder."
The latest research, reported in two papers appearing in the Nov. 16 issue of Cell, was conducted by scientists at The Rockefeller University in collaboration with researchers from the Emory University School of Medicine. One study was initiated by Darnell, head of the Laboratory of Molecular Neuro-Oncology at Rockefeller, and the other by Stephen T. Warren, Ph.D., an investigator at Emory University School of Medicine and Howard Hughes Medical Institute.
Fragile X syndrome, the second leading cause of mental retardation after Down syndrome and the most common cause of inherited mental retardation, affects approximately 1 in 2,000 males and 1 in 4,000 females worldwide. Symptoms include mild to moderate cognitive and behavioral deficits as well as subtle facial malformations. In addition, the brain cells, or neurons, of people with the disease have abnormal physical features: their "dendritic spines" - the finger-like projections on the ends of neurons that are required for communication with other neurons - are unusually long and spindly.
The disease originates when genetic mutations in the FMRP gene, which lies on the X chromosome, cause FMRP not to be produced. But unlike the well-studied Down syndrome, which occurs when a portion of a chromosome is duplicated in the womb, much remains unclear about the molecular basis of fragile X syndrome.
"The problem of fragile X is intriguing, because the loss of a single protein causes a variety of behavioral and physical changes," says Jennifer Darnell, Ph.D., lead author of one of the Cell reports and a research assistant professor at Rockefeller. "Before this, the consequences of losing the fragile X mental retardation protein on other brain proteins was unknown."
Previously, it was known that FMRP, first identified a decade ago, binds to messenger RNA (mRNA) molecules - which carry genetic information (DNA) from a body cell's nucleus to its protein-making machinery - yet the specific mRNAs involved as well as the overall purpose of this protein remained elusive.
Now, the researchers present several important clues, which together suggest that FMRP may turn up or down the production of certain brain proteins by binding to their mRNA molecules, and thus influencing the cell's protein-making machinery. This type of protein regulation is a crucial aspect of every cell's life, and in the case of brain cells, is essential for learning and memory formation. A key feature of the current work is the identification of the specific mRNAs that FMRP binds to, as well as the finding that these molecules are misregulated in the cells of fragile X patients.
"We found FMRP binding sites in a population of mRNAs shown to be abnormally regulated in fragile X patients," says Jennifer Darnell. "The proteins coded for by these mRNAs are likely to underlie the problems these patients have."
Darnell, a Rockefeller alumna, first became interested in FMRP about five years ago because of its similarity to another RNA-binding protein, Nova, under study in the laboratory of her husband, Robert Darnell. She identified the FMRP mRNA targets by first discovering that FMRP recognizes and tightly binds loop-like structures in RNA, called G-quartets, which represent novel human RNA-binding sites. This finding is intriguing because these structures, which resemble in appearance loose knots along a string, are typically found in DNA and not RNA; the only known case of these structures existing in RNA is in bacteriophage RNA, where, perhaps not coincidentally, they play a role in mRNA regulation. A bacteriophage is a tiny virus that only infects bacteria.
After searching a computer database of known mRNAs for the G-quartets, she hit upon a significant finding: several of the the mRNAs targeted by FMRP, and their corresponding proteins, play a role in learning and memory, the development of the bones of the face and in the formation of the nervous system - all brain activities involved in fragile X syndrome.
"Most of the mRNAs we identified as FMRP targets are involved in some aspect of synaptic biology," says Jennifer Darnell. Synapses are the point of contact between neurons, where information is exchanged between the axon of one neuron to the dendrite of a second neuron.
"It is possible that FMRP is responsible for shuttling certain proteins out to the individual dendritic spines of neurons, and/or subsequently activating them at the appropriate time during development, as well as during adult memory formation," says Jennifer Darnell. "This would explain how specific neuronal connections are strengthened to form memories."
Meanwhile, Warren's group at Emory also had independently identified mRNA targets of FMRP, only using a different technique called microarray, or "DNA chip," analysis. The two groups, which had initially met at the 2001 annual meeting on fragile X syndrome at Cold Spring Harbor Laboratory, collaborated and, working together, discovered that nearly 70 percent of Warren's targets contained the G-quartets.
Finally, the researchers demonstrated that these recently characterized FMRP targets - identified in a test tube in Jennifer Darnell's case - are in fact misregulated in patients' cells, thereby linking their molecular findings to what's really happening in people's bodies.
Because FMRP seems to play a role in both the developing and the adult brain, it may eventually be possible to treat some of the symptoms of fragile X syndrome. In addition, the discovery of several specific mRNAs involved in the disease has opened the door to new drug targets; it one day may be possible to manipulate the individual mRNAs, or proteins, responsible for the various symptoms of fragile X as a means to treat the disease.
The research was funded by the FRAXA Research Foundation, and by the National Institute of Child Health and Human Development and the National Institutes of Health.
John D. Rockefeller founded Rockefeller University in 1901 as The Rockefeller Institute for Medical Research. Rockefeller scientists have made significant achievements, including the discovery that DNA is the carrier of genetic information. The University has ties to 21 Nobel laureates, six of which are on campus. Rockefeller University scientists have received this award for two consecutive years: neurobiologist Paul Greengard, Ph.D., in 2000 and cell biologist Günter Blobel, M.D., Ph.D., in 1999, both in Physiology or Medicine. At present, 33 faculty are elected members of the U.S. National Academy of Sciences. Celebrating its Centennial anniversary in 2001, Rockefeller - the nation's first biomedical research center - continues to lead the field in both scientific inquiry and the development of tomorrow's scientists.
The above post is reprinted from materials provided by Rockefeller University. Note: Materials may be edited for content and length.
Cite This Page: